Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies

INTRODUCTION: In a subset of patients with asthma, standard-of-care treatment does not achieve disease control, highlighting the need for novel therapeutic approaches. Lebrikizumab is a humanised, monoclonal antibody that binds to and blocks interleukin-13 activity. METHODS: LUTE and VERSE were repl...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanania, Nicola A, Noonan, Michael, Corren, Jonathan, Korenblat, Phillip, Zheng, Yanan, Fischer, Saloumeh K, Cheu, Melissa, Putnam, Wendy S, Murray, Elaine, Scheerens, Heleen, Holweg, Cecile TJ, Maciuca, Romeo, Gray, Sarah, Doyle, Ramona, McClintock, Dana, Olsson, Julie, Matthews, John G, Yen, Karl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Respiratory Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515999/
https://www.ncbi.nlm.nih.gov/pubmed/26001563
http://dx.doi.org/10.1136/thoraxjnl-2014-206719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515999/
https://www.ncbi.nlm.nih.gov/pubmed/26001563
http://dx.doi.org/10.1136/thoraxjnl-2014-206719

Ejemplares similares